Vereinigtes Königreich - Englisch - MHRA (Medicines & Healthcare Products Regulatory Agency)

p.i.e. pharma ltd - glycopyrronium bromide - oral tablet - 2mg

Vereinigtes Königreich - Englisch - MHRA (Medicines & Healthcare Products Regulatory Agency)

de pharmaceuticals - glycopyrronium bromide - oral tablet - 1mg

Vereinigtes Königreich - Englisch - MHRA (Medicines & Healthcare Products Regulatory Agency)

de pharmaceuticals - glycopyrronium bromide - oral tablet - 2mg

Vereinigtes Königreich - Englisch - MHRA (Medicines & Healthcare Products Regulatory Agency)

teva uk ltd - glycopyrronium bromide - oral tablet - 1mg

Vereinigtes Königreich - Englisch - MHRA (Medicines & Healthcare Products Regulatory Agency)

teva uk ltd - glycopyrronium bromide - oral tablet - 2mg

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - glycopyrronium bromide, quantity: 63 microgram (equivalent: glycopyrronium, qty 50 microgram); indacaterol maleate, quantity: 143 microgram (equivalent: indacaterol, qty 110 microgram) - inhalation, powder for - excipient ingredients: lactose monohydrate; magnesium stearate - ultibro breezhaler 110/50 is indicated as a once-daily maintenance bronchodilator treatment to relieve symptoms in patients with chronic obstructive pulmonary disease (copd), and for the reduction of exacerbations of copd in patients with a history of exacerbations.

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - glycopyrronium bromide, quantity: 200 microgram - injection, solution - excipient ingredients: water for injections; hydrochloric acid; sodium chloride - 1. as a preoperative antimuscarinic to reduce salivary, tracheobronchial and pharyngeal secretions, and to reduce the acidity and volume of the gastric contents. ,2. as a preoperative or intra-operative antimuscarinic to attenuate or prevent intraoperative bradycardia associated with the use of suxamethonium or due to cardiac vagal reflexes. ,3. to protect against the peripheral muscarinic actions (e.g. bradycardia and excessive secretions) of anticholinesterases such as neostigmine or pyridostigmine given to reverse neuromuscular blockade produced by non-depolarising muscle relaxants.

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

grand medical pty ltd - glycopyrronium bromide, quantity: 63 microgram (equivalent: glycopyrronium, qty 50 microgram); mometasone furoate, quantity: 80 microgram; indacaterol acetate, quantity: 173 microgram (equivalent: indacaterol, qty 150 microgram) - capsule, hard - excipient ingredients: lactose monohydrate; magnesium stearate - zimbus breezhaler is indicated as a maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long-acting beta2-agonist and an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous year.

Neuseeland - Englisch - Medsafe (Medicines Safety Authority)

max health limited - glycopyrronium bromide 0.5 mg/ml; neostigmine metilsulfate 2.5 mg/ml - solution for injection - active: glycopyrronium bromide 0.5 mg/ml neostigmine metilsulfate 2.5 mg/ml excipient: citric acid citric acid monohydrate dibasic sodium phosphate dodecahydrate sodium hydroxide water for injection - reversal of residual non-depolarising (competitive) neuromuscular block.

Vereinigtes Königreich - Englisch - MHRA (Medicines & Healthcare Products Regulatory Agency)

colonis pharma ltd - glycopyrronium bromide - oral solution - 200microgram/1ml